224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
Approximately 224 adults will be enrolled in an outpatient Phase III study to compare the safety and efficacy of topically applied magainin peptide (MSI-78) to that of ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic, in the treatment of infected diabetic foot ulcers. This is a randomized, controlled, double-blind trial that will involve twenty or more clinical centers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
342
Seattle VA Medical Center
Seattle, Washington, United States
Reduction in clinical signs and symptoms of infection
Measure will be a comparison of the reduction in clinical signs and symptoms of infection between MSI-78 topical therapy and conventional oral antibiotic therapy
Time frame: Study day 10
Microbiological response
Measure microbiological response to therapy
Time frame: Study day 10
Wound infection score
Measure wound infection score
Time frame: Study day 10
Total wound score
Measure total wound score
Time frame: Study day 10
Wound area
Measure wound area.
Time frame: Study day 10
Wound depth.
Measure wound depth.
Time frame: Study day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.